Milford Funds Ltd. Takes $77.74 Million Position in Boston Scientific Corporation $BSX

Key Points

• Milford Funds Ltd. opened a new position in Boston Scientific, buying 815,279 shares worth about $77.7 million, making BSX its 25th largest holding.
• Boston Scientific continues to attract major institutional interest, with firms like Vanguard, Capital World Investors, and Norges Bank adding to or initiating large stakes; hedge funds and other institutional investors own 89.07% of the stock.
• The company remains under pressure from lowered/uncertain guidance and a recent share price decline, but analysts are still broadly positive, and Boston Scientific also announced a $5 billion share buyback plus insider buying by directors.

Milford Funds Ltd. purchased a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 815,279 shares of the medical equipment provider's stock, valued at approximately $77,737,000. Boston Scientific makes up 1.5% of Milford Funds Ltd.'s investment portfolio, making the stock its 25th largest holding. Milford Funds Ltd. owned approximately 0.05% of Boston Scientific as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider's stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares in the last quarter. Capital World Investors grew its position in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider's stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Invesco Ltd. grew its position in shares of Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock valued at $1,656,131,000 after purchasing an additional 111,826 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Boston Scientific by 0.9% in the third quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider's stock valued at $1,406,129,000 after purchasing an additional 128,188 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation NYSE: BSX - Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Trading Down 0.7%

BSX opened at $46.83 on Friday. Boston Scientific Corporation has a 52 week low of $45.99 and a 52 week high of $109.50. The business has a fifty day simple moving average of $56.37 and a 200-day simple moving average of $74.95. The firm has a market cap of $69.60 billion, a P/E ratio of 19.59, a P/E/G ratio of 0.89 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the business posted $0.75 earnings per share. The company's quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's board believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the business's stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the business's stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares of the company's stock, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last ninety days. Company insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BSX shares. UBS Group dropped their price target on Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research report on Tuesday, March 17th. Jefferies Financial Group lowered their price objective on Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Barclays lowered their price objective on Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 28th. Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a research report on Wednesday, May 27th. Finally, Daiwa Securities Group lowered Boston Scientific from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.08.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.